SI-BONE, Inc. Announces Journal of Bone and Joint Surgery (JBJS) Publishes 2-Year Results from iMIA, a European Multicenter Randomized Controlled Trial (RCT) of SI Joint Fusion with iFuse Implant System® vs Conservative Care
This is the 67th peer-reviewed iFuse publication and shows rapid and sustained improvements in pain, patient function and quality of life, consistent with INSITE, a U.S. RCT published in August, 2016
SANTA CLARA, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company that pioneered minimally invasive surgery of the sacroiliac (SI) joint with the iFuse Implant System® (iFuse), announced publication of 2-year results from iMIA (iFuse Implant System Minimally Invasive Arthrodesis; ClinicalTrials.gov ID NCT01741025), a multicenter European RCT in the Journal of Bone and Joint Surgery (JBJS).
iMIA is a Level 1 RCT, conducted at nine hospitals in four countries in Europe, that assessed the safety and effectiveness of SI joint fusion (SIJF), also referred to as SI joint arthrodesis in the manuscript, with the triangular iFuse Implants compared to conservative management (CM) in patients with chronic SI joint dysfunction. The JBJS publication, titled Randomized Trial of Sacroiliac Joint Arthrodesis Compared with Conservative Management for Chronic Low Back Pain Attributed to the Sacroiliac Joint,1 showed that minimally invasive SIJF with iFuse Implants was safe and more effective than CM in relieving pain, reducing disability, and improving patient function and quality of life at two years.
“What I find remarkable is the consistency of the results between the 2-year iMIA and 2-year INSITE RCTs,” said David Polly, Jr., MD, Professor, Department of Orthopedic Surgery at the University of Minnesota. “The studies, which were well designed and well executed, were conducted at a combined 28 different centers on two different continents, yet the results are almost identical, which only further validates the effectiveness of the use of the iFuse triangular titanium implants for the treatment of patients with chronic SI joint dysfunction who no longer respond to conservative treatment.”
The iMIA 2-year results were published in JBJS, which has an impact factor of 4.84, the highest among orthopedic journals, and is a highly valued source of information for orthopedic surgeons and researchers. As such, this publication, which is the 67th peer-reviewed iFuse publication, is a significant indication of the broad acceptance of SI joint surgery as an important topic of study in orthopedics.
“The publication of this Level 1 study in a prestigious orthopedic journal such as JBJS is an important milestone signaling recognition of the sacroiliac joint, like all other joints in the human body, as a pain generator and acknowledgement of the high quality of evidence that supports iFuse as an effective minimally invasive procedure for patients with SI joint pain”, said Daniel Cher, MD, Vice President of Clinical Affairs at SI-BONE, Inc.
As shown in Figures 1 and 2 below, 2-year results from iMIA were remarkably consistent with 2-year results from INSITE (Investigation of Sacroiliac Fusion Treatment – NCT01681004), the RCT conducted at 19 institutions in the U.S. and published in August, 2016 in the International Journal of Spine Surgery.2
In the iMIA study, 103 subjects were randomly assigned to CM (n=51) or SIJF (n=52) between June 6, 2013 and May 15, 2015. At 2 years, mean low back pain (as measured on the Visual Analog Scale, or VAS) improved by 45 points in the SIJF group and 11 points in the CM group (mean difference between groups 34 points, p<0.0001). Mean ODI improved by 26 points in the SIJF group and 8 points in the CM group (mean difference 18 points, p<0.0001). Parallel improvements were seen in leg pain and several quality of life measures. Moreover, objective improvements were observed in SI joint function, including active straight leg raise test and a number of positive physical examination signs for SI joint pain. In the SIJF group, the prevalence of opioid use decreased from 56% at baseline to 33% at 2 years (p<0.01), while no significant change was observed in the CM group (47.1% and 45.7%). Subjects in the CM group who derived minimal benefit after 6 months of CM showed improvements in all measures similar to those originally assigned to SIJF after crossing over to surgery. One case of postoperative nerve impingement occurred in the SIJF group. The full article can be found at the following link: https://journals.lww.com/jbjsjournal/Fulltext/2019/03060/Randomized_Trial_of_Sacroiliac_Joint_Arthrodesis.4.aspx
SI-BONE is a medical device company that pioneered the iFuse Implant System, a minimally invasive surgical system for fusion of the sacroiliac joint to treat sacroiliac joint dysfunction. The SI joint is the last major joint with a clinically proven surgical treatment. The iFuse Implant, commercially available since 2009, is the only SI joint fusion device supported by multiple prospective clinical studies showing improved pain, patient function and quality of life resulting from treatment. There are more than 65 peer-reviewed publications supporting the safety, durable effectiveness, and biomechanical and economic benefits unique to the iFuse Implant (www.si-bone.com/results). This body of evidence has enabled multiple government and private insurance payors to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System.
The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit.
SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2019 SI-BONE, Inc. All Rights Reserved. 10309.030719
- Dengler J, Kools D, Pflugmacher R, Gasbarrini A, Prestamburgo D, Gaetani P, Cher D, Van Eeckhoven E, Annertz M, Sturesson B. Randomized Trial of Sacroiliac Joint Arthrodesis Compared with Conservative Management for Chronic Low Back Pain Attributed to the Sacroiliac Joint. J Bone Joint Surg. 2019;101(5):400-411. doi: 10.2106/JBJS.18.00022
- Polly DW, Swofford J, Whang PG, Frank CJ, Glaser JA, Limoni RP, Cher DJ, Wine KD, Sembrano JN, and the INSITE Study Group. Two-Year Outcomes from a Randomized Controlled Trial of Minimally Invasive Sacroiliac Joint Fusion vs. Non-Surgical Management for Sacroiliac Joint Dysfunction. Int J Spine Surg. 2016;10:Article 28. doi: 10.14444/3028
For SI-BONE, Inc.:
Vice President of Marketing
Photos accompanying this announcement are available at
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
LGC Capital announces that it has increased its ownership to 40.4% of Little Green Pharma in Australia22.5.2019 16:25:00 CEST | Pressemelding
MONTRÉAL, May 22, 2019 (GLOBE NEWSWIRE) -- LGC Capital Ltd. (TSXV: LG) (OTCQB: LGGCF) ("LGC" or the “Corporation”) announces that after much negotiation, it has successfully acquired, from a non-executive founder, additional shares in Australia’s licensed medical cannabis producer Little Green Pharma (LGP) bringing its ownership from 14.1% up to 40.4%. LGP was the first, and is currently the only, domestic cannabis company in Australia producing a locally grown medicinal cannabis medicine for patients. LGC believes the opportunity to increase its ownership in LGP creates significant value for its shareholders and enables the Corporation to further take part in the rapidly expanding Australian medical cannabis market. Little Green Pharma has had over 400 patients approved in Australia, with new patients increasing exponentially month-over-month. The Australian industry represents one of the fastest growing international medical cannabis markets globally, with approximately 6,400 SAS B f
Virtusa recognized as a Visionary in the Magic Quadrant for CRM and Customer Experience Implementation Services, Worldwide22.5.2019 16:05:00 CEST | Pressemelding
SOUTHBOROUGH, Mass., May 22, 2019 (GLOBE NEWSWIRE) -- Virtusa Corporation (NASDAQ GS:VRTU), a global provider of digital strategy, digital engineering, and IT outsourcing services that accelerates business outcomes for its clients, today announced that Gartner, Inc. has positioned Virtusa in the Visionaries Quadrant of the 2019 Magic Quadrant for CRM and Customer Experience (CX) Implementation Services, Worldwide. The report evaluated Virtusa along with 17 other companies in CRM and Customer Experience Implementation Services. Virtusa was one of only three companies to be categorized as a Visionary. According to Gartner, “The CX and CRM implementation service market is completing the shift from the implementation of core CRM technology to complex initiatives that not only transform the front office but integrate across the full enterprise’s operations. Customers now demand that organizations provide them with a continuous experience, preserving continuity of user experience across trad
InnovMetric Launches PolyWorks® Metrology Suite 201922.5.2019 15:00:00 CEST | Pressemelding
Facilitates Deployment of PolyWorks|Inspector™ in Production and Accelerates CNC CMM Measurement Sequences QUEBEC CITY, May 22, 2019 (GLOBE NEWSWIRE) -- InnovMetric Software Inc., the leading provider of universal 3D metrology software solutions, today announced the launch of the 2019 release of the PolyWorks Metrology Suite. This latest major release delivers new object measurement scripts that open the door to all the custom measurement techniques of clients within the standard PolyWorks workflow, as well as a new assisted sequencing approach that promises to greatly accelerate the time to set up CMM sequences. “Simplifying the lives of our customers while keeping them fully in control. This statement embodies the development philosophy behind the PolyWorks Metrology Suite and the latest 2019 release,” said Marc Soucy, President of InnovMetric. He added, “With its outstanding innovations that combine increased simplicity with important time savings, we are proud to bring the producti
Brookfield Asset Management Announces Renewal of Normal Course Issuer Bid22.5.2019 12:55:00 CEST | Pressemelding
BROOKFIELD, May 22, 2019 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (NYSE: BAM) (TSX: BAM.A) (EURONEXT: BAMA) (“Brookfield”) today announced it has received approval from the Toronto Stock Exchange (“TSX”) for the renewal of its normal course issuer bid to purchase up to 82,530,440 Class A Limited Voting Shares (“Class A Shares”), representing 10% of the public float of Brookfield’s outstanding Class A Shares. Purchases under the bid will be made through the facilities of the TSX, the New York Stock Exchange (“NYSE”), and/or alternative trading systems. The period of the normal course issuer bid will extend from May 24, 2019 to May 23, 2020, or an earlier date should Brookfield complete its purchases. Brookfield will pay the market price at the time of acquisition for any Class A Shares purchased or such other price as may be permitted. As at May 17, 2019, the number of Class A Shares issued and outstanding totalled 994,568,660, of which 825,304,404 shares represented the pub
Phenom People Launches University Recruiting, SMS & Internal Mobility Chatbot22.5.2019 10:00:00 CEST | Pressemelding
Product Innovations to Support Demand for Talent Experience Management LONDON, May 22, 2019 (GLOBE NEWSWIRE) -- Phenom People, the global leader in Talent Experience Management (TXM), has announced several new features for the Phenom Talent Experience Management platform, adding University Recruiting, SMS, WhatsApp messaging and Internal Mobility chatbot functionality to further support the demands of the new talent economy, which is undergoing major technological and societal shifts. The Phenom Talent Experience Management platform connects the interactions of the four key experiences in the talent lifecycle: candidates, recruiters, employees and management, and delivers a single platform to unify them. Cross-functional insights can be used to power a more personalised and effective experience that meets the demands of today’s talent. The Phenom Talent Experience Management platform furthers chief human resources officers’ top responsibilities across talent acquisition, talent managem
Phenom People Unveils Talent Experience Management Platform Single Platform for Every Talent Experience22.5.2019 10:00:00 CEST | Pressemelding
LONDON, May 22, 2019 (GLOBE NEWSWIRE) -- Phenom People has announced Talent Experience Management (TXM) as the holistic approach and SaaS platform to connect every interaction throughout the talent lifecycle by delivering personalised experiences. Talent Experience Management unifies technology and experience design to enhance the talent journey, transforming candidates to employees to brand advocates, while recruiters and management boost productivity and communicate seamlessly. Despite spending massive amounts of money on new investments in HR technology, today’s chief human resources officers still struggle to change the stereotype of their organisation from a cost center to a revenue generator for talent acquisition, talent management and talent evolution. With Talent Experience Management, Phenom People is helping organisations manage the new talent economy, which is undergoing major technological and societal shifts, with a solution that addresses the different needs and experien